Protalix BioTherapeutics Inc (PLX)
1.17
+0.04
(+3.54%)
USD |
NYAM |
May 16, 16:00
1.165
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Cash from Financing (Quarterly): 0.00 for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 0.00 |
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 10.43M |
March 31, 2023 | 14.23M |
December 31, 2022 | 4.075M |
September 30, 2022 | 1.52M |
June 30, 2022 | 2.643M |
March 31, 2022 | 0.00 |
December 31, 2021 | -4.046M |
September 30, 2021 | -25.99M |
June 30, 2021 | 0.00 |
March 31, 2021 | 42.11M |
December 31, 2020 | 4.652M |
September 30, 2020 | 4.472M |
June 30, 2020 | -1.264M |
March 31, 2020 | 38.61M |
December 31, 2019 | |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | -4.752M |
March 31, 2018 |
Date | Value |
---|---|
December 31, 2017 | 0.00 |
September 30, 2017 | 9.542M |
June 30, 2017 | -4.235M |
March 31, 2017 | -6.726M |
December 31, 2016 | 19.70M |
September 30, 2016 | 0.00 |
June 30, 2016 | 0.00 |
March 31, 2016 | |
December 31, 2015 | 6.101M |
September 30, 2015 | 0.00 |
June 30, 2015 | 0.534M |
March 31, 2015 | |
December 31, 2014 | 0.003M |
September 30, 2014 | 0.012M |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.031M |
December 31, 2013 | -0.068M |
September 30, 2013 | 66.93M |
June 30, 2013 | 0.03M |
March 31, 2013 | |
December 31, 2012 | 0.134M |
September 30, 2012 | -0.14M |
June 30, 2012 | 0.99M |
March 31, 2012 | 25.57M |
December 31, 2011 | 0.014M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-25.99M
Minimum
Sep 2021
42.11M
Maximum
Mar 2021
4.813M
Average
--
Median
Jun 2019
Cash from Financing (Quarterly) Benchmarks
Agenus Inc | 14.83M |
InfuSystems Holdings Inc | 0.632M |
AIM ImmunoTech Inc | 0.147M |
Perspective Therapeutics Inc | 0.352M |
Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 4.188M |
Cash from Investing (Quarterly) | -0.606M |
Free Cash Flow | 4.369M |
Free Cash Flow Per Share (Quarterly) | 0.0492 |
Free Cash Flow to Equity (Quarterly) | 3.421M |
Free Cash Flow to Firm (Quarterly) | 3.59M |
Free Cash Flow Yield | 4.59% |